Navigation Links
Schering-Plough Announces FDA Approval of PEGINTRON(TM) and REBETOL(R) Combination Therapy for Treating Pediatric Hepatitis C
Date:12/12/2008

of patients with hepatitis C."

The approval of PEGINTRON for the pediatric indication is based on the results of a clinical trial in 107 previously untreated patients 3 to 17 years of age with chronic hepatitis C and compensated liver disease. In the study, patients infected with HCV genotype 1 or 4 and those with HCV genotype 3 with HCV RNA greater than 600,000 IU/mL (high viral load [HVL]) were assigned 48 weeks of therapy, while those infected with HCV genotype 2 or 3 with HCV RNA less than 600,000 IU/mL (low viral load [LVL]) received 24 weeks of therapy. Of the patients with HCV genotype 1, 4 or 3 HVL who were assigned to 48 weeks of treatment, 55 percent achieved SVR. As with adult patients, SVR in pediatric patients with HCV genotype 2 or 3 LVL was much higher than in those with genotype 1; the SVR rate was 96 percent in children with HCV genotype 2 or 3 LVL.

In the pediatric population, the recommended dose of PEGINTRON, based on body surface area, is 60 mcg/m2/week subcutaneously in combination with 15 mg/kg/day of REBETOL, based on body weight, orally in two divided doses. The treatment duration for patients with HCV genotype 1 is 48 weeks and for patients with HCV genotype 2 or 3 it is 24 weeks. Patients receiving PEGINTRON combination therapy (excluding those with HCV genotype 2 or 3) should be discontinued from therapy at week 12 if their HCV RNA dropped less than 2 log10 compared to pretreatment or at 24 weeks if they have detectable HCV RNA at treatment week 24.

During the course of therapy lasting up to 48 weeks in patients 3 to 17 years of age, weight loss and growth inhibition were common. Some children who experienced growth inhibition during therapy still had inhibited growth velocity 6 months following the end of treatment. Most common adverse reactions (more than 25 percent) observed in these studies were pyrexia, headache, neutropenia, fatigue, anorexia, injection site ery
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
2. Schering-Plough Schedules Conference Call and Webcast for 2007 Third Quarter Earnings
3. Schering-Plough Reports Financial Results for Third Quarter of 2007
4. Schering-Plough CEO Calls for Four-Pronged Approach to Improving Current Health Care Environment
5. Schering-Plough Reports U.S. District Court for District of Massachusetts Finds No Liability for Subsidiary in AWP Case
6. Schering-Plough to Webcast CFO Robert J. Bertolinis Presentation at 2007 Credit Suisse Health Care Conference
7. Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V.
8. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
9. Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
10. Schering-Plough Board Elects Dr. Craig B. Thompson as a Director
11. Schering-Plough CEO to Buy $2 Million in Common Shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... MIDDLEBURY, CT (PRWEB) July 11, 2014 ... announced today the launch of the Timex Performance Network, ... product information, training plans, athlete testimonials, seasonal news and ... Performance Network will capitalize on the legacy of the ... online destination for runners and endurance athletes nationwide. The ...
(Date:7/11/2014)... 11, 2014 (HealthDay News) -- Polio is history in ... like Afghanistan, Nigeria and Pakistan. Giving vaccinated children an ... immunity and help eradicate the highly infectious disease, a ... highly effective, immunity wanes as early as a year ... infected and contribute to the spread of the disease, ...
(Date:7/11/2014)... AngelWeddingDress is now providing worldwide clients with ... ”. When it comes to buying summer wedding dresses ... the unlimited stock of beautiful wedding gowns. Recently, the ... summer wedding gowns. , The company’s current promotion ... pace with the newest fashion trends. The top experts ...
(Date:7/11/2014)... Alliance Labs announced that they will be featured ... Jr, airing later this year 2014, via Discovery Channel. ... Innovations will explore DocuSol® Kids, a mini-enema containing a ... base designed to give adolescents general constipation relief. Viewers ... hyperosmotic laxative by drawing water into the bowel from ...
(Date:7/11/2014)... July 11, 2014 Anterior Cruciate Ligament ... but the type of material used to create a ... the game, say researchers presenting their work today at ... Sports Medicine ( AOSSM ). , “Our ... allografts (tissue harvested from a donor) fail more frequently ...
Breaking Medicine News(10 mins):Health News:Timex Announces Launch of Timex Performance Network 2Health News:Researchers Assess New Way to Boost Polio Immunity 2Health News:AngelWeddingDress Will Continuously Unveil More Summer Wedding Dresses for Loyal Clients 2Health News:Alliance Labs & DocuSol® to be Featured in Upcoming Episode of Innovations 2Health News:ACL Reconstructions May Last Longer With Autografts 2
... cases from two severely disabled children. These cases were mainly ... negligent medical advice. //One such is that of Alexia Harriton, ... that her family doctor had not informed her mother about ... is that of a five-year-old Keeden Waller who was born ...
... The Australian Medical Association announced today that six doctors ... the implementation of new rosters,//which they contend could harm ... doctors are simply expressing displeasure over the new working ... the resignation of the doctors was effective from this ...
... the doctors of the Royal College of Physicians it was ... //It was found that about 73% of the doctors were ... dying where it states that the doctors should be given ... the terminally ill person. But the physicians of the ...
... Office workers are at an increased risk of being affected ... hours on their computer.// DVT is a condition that gives ... the heat or the lung with often fatal consequences. ,This ... e-thrombosis. The condition came to light after it emerged that ...
... take place on June 18 has been advanced to ... the advancement but the centre is against the advancement ... the death of about 1,000 to 2,000 lives every ... children in Muslim-dominated areas are dying. About 5.2 million ...
... from Uttar Pradesh has disproved the claims of health authorities ... been reported in the state. ,This is reported ... (NPSP) issued here this month. ,Some of the ... by the state but also by international agencies like UNICEF, ...
Cached Medicine News:Health News:Fresh Polio Cases Reported In Uttar Pradesh 2
(Date:1/15/2014)... 2014  Novation, the leading health care supply chain expertise, ... reseller (VAR) national contracts that expand its portfolio to ... lower costs. These include manufacturer product and service agreements, ... and ongoing IT consulting support. New ...
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Intellectual Property Insurance for Medical-related Products and Services 2
... Incorporated (NASDAQ: VPHM ) today announced the ... ILNS) to its clinical stage drug candidate, OX1, being ... rare, hereditary, progressive neurodegenerative disease. OX1, ... molecule that has potent anti-oxidant properties that can protect ...
... KIRKLAND, Wash., Sept. 29, 2011 Cardiac Dimensions®, Inc. ... Mark approval for a newly enhanced version of its ... heart failure patients suffering from functional mitral regurgitation (FMR). ... initiate a commercial launch of the enhanced device in ...
Cached Medicine Technology:ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia 2ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia 3ViroPharma Licenses Rights From Intellect Neurosciences for Product Candidate for Friedreich's Ataxia 4Cardiac Dimensions® Receives CE Mark Approval for Enhanced CARILLON® Mitral Contour System™ 2Cardiac Dimensions® Receives CE Mark Approval for Enhanced CARILLON® Mitral Contour System™ 3
... Advanced diagnostic capabilities combined with ease of ... product in its class. Ideal for office ... complete system for Uroflowmetry, cystometry, leak point ... configurations are available which make the OM-5 ...
... with ease of use make the OM-5 ... Ideal for office or hospital-based urodynamics, the ... cystometry, leak point pressure, or urethral pressure ... make the OM-5 flexible enough to meet ...
... with ease of use make the OM-5 ... Ideal for office or hospital-based urodynamics, the ... cystometry, leak point pressure, or urethral pressure ... make the OM-5 flexible enough to meet ...
... capabilities combined with ease of use make ... its class. Ideal for office or hospital-based ... for Uroflowmetry, cystometry, leak point pressure, or ... available which make the OM-5 flexible enough ...
Medicine Products: